Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTheriva publishes Phase 1 trial results for VCN-01 showing 17-month survival in head & neck cancer
Filed June 11, 2026 · Period ending June 11, 2026 · ~1 min read
Key Changes
-
high
Phase 1 trial of VCN-01 combined with durvalumab achieved median overall survival of 17.3 months in the high-dose sequential arm for heavily pre-treated head and neck cancer patients who had failed prior checkpoint inhibitors.
Item 7.01: Press Release verify on EDGAR → -
high
Trial results published in Clinical Cancer Research journal, providing peer-reviewed validation of VCN-01's clinical data in 20 patients with refractory or metastatic head and neck squamous cell carcinoma.
Item 7.01: Press Release verify on EDGAR → -
medium
Biomarker data confirmed VCN-01 successfully replicated inside tumors, with PH20 enzyme levels elevated in all tested patients and detectable for up to 28 days, supporting the therapy's mechanism of action.
Item 7.01: Press Release verify on EDGAR → -
high
Tumor biopsies showed increased PD-L1 expression after VCN-01 treatment that correlated with survival, suggesting the virus may enhance effectiveness of checkpoint inhibitors like durvalumab in combination therapy.
Item 7.01: Press Release verify on EDGAR → -
medium
Progression-free survival ranged from 1.6 to 3.7 months across three treatment arms, with the sequential low-dose arm showing longest PFS at 3.7 months in this difficult-to-treat patient population.
Item 7.01: Press Release verify on EDGAR →
Summary
Theriva Biologics announced publication of Phase 1 clinical trial results for VCN-01, its lead oncolytic virus candidate, in the peer-reviewed journal Clinical Cancer Research. The trial tested VCN-01 combined with durvalumab in 20 patients with advanced head and neck cancer who had already failed multiple treatments including checkpoint inhibitors.
The high-dose sequential treatment arm achieved median overall survival of 17.3 months, a notable result for this heavily pre-treated population. The trial provided important proof-of-concept data showing VCN-01 successfully replicated inside tumors and triggered immune system activation.
Biomarker analysis revealed the virus increased PD-L1 expression in tumors, which correlated with patient survival and suggests VCN-01 may make previously unresponsive tumors more susceptible to checkpoint inhibitor therapy. Tumor biopsies also showed increased infiltration of cancer-killing T cells and reduced immune suppression. Retail investors should watch for announcements about Phase 2 trial initiation or expansion studies, as peer-reviewed publication of positive Phase 1 data often precedes advancement to larger trials. The combination approach targeting both viral tumor destruction and immune activation represents a differentiated strategy in the competitive oncology space.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
clinical and translational results from VCN-01’s Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma (HNSCC) were recently published on-line first in the journal Clinical Cancer Research.
The company disclosed that results from a Phase 1 clinical trial of VCN-01 in head and neck cancer patients have been published in Clinical Cancer Research. The trial tested VCN-01 (an oncolytic virus) combined with durvalumab (an immunotherapy drug) in 20 patients whose disease had progressed despite prior treatments including checkpoint inhibitors.
Added in current filing · verify on EDGAR →
Median overall survival (OS) was 10.3 months in Arm I LD, 15.5 months in Arm II LD, and 17.3 months in Arm II HD.
The trial showed median overall survival ranging from 10.3 to 17.3 months across three treatment arms in patients with refractory or metastatic head and neck cancer. The sequential high-dose arm (Arm II HD) achieved the longest survival at 17.3 months, which is notable for this heavily pre-treated patient population.
Added in current filing · verify on EDGAR →
Circulating levels of the stroma-degrading hyaluronidase enzyme PH20 (expressed during selective VCN-01 intratumoral replication) increased significantly after VCN-01 administration in all tested patients, peaking on day 3-8 for most patients and detectable until day 28 in 11 of 12 patients.
The trial demonstrated that VCN-01 successfully replicated inside tumors, as evidenced by increased blood levels of PH20 enzyme (which the virus produces). This biomarker evidence supports the mechanism of action and shows the virus was active in nearly all tested patients for up to 28 days.
Added in current filing · verify on EDGAR →
Upregulation of CD8 and IDO was observed in tumor biopsy samples, implying increased tumor infiltration with activated cytotoxic T cells – historically associated with increased HNSCC patient survival. Diminished levels of FoxP3, CD25, and CTLA4 were also observed, consistent with a reduction in tumor Tregs and inhibition of tumor immunosuppression.
Tumor biopsies showed biological changes indicating increased immune system attack on tumors (more CD8 T cells) and reduced immune suppression (fewer regulatory T cells). These changes are historically linked to better survival outcomes in head and neck cancer patients and support the combination therapy's mechanism.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 11, 2026, the Company issued a press release announcing that clinical and translational results from VCN-01’s Phase 1 clinical trial in HNSCC were recently published on-line first in the journal Clinical Cancer Research.
The company disclosed that results from its VCN-01 Phase 1 clinical trial in head and neck squamous cell carcinoma (HNSCC) were published in Clinical Cancer Research journal. This represents a milestone in advancing the company's lead product candidate through clinical development and peer-reviewed scientific validation.
Added in current filing · verify on EDGAR →
The trial enrolled 20 adult patients with refractory or metastatic HNSCC, whose disease progressed despite previous therapies, including anti-PD-(L)1 immune checkpoint inhibitors. Six patients were enrolled into the concomitant Arm I LD of the study and were administered IV low dose VCN-01 (3.3E12 virus particles; LD) four hours prior to a fixed IV dose of durvalumab (1500 mg/q4w). Eight patients were enrolled into the sequential Arm II LD of the study, receiving low dose IV VCN-01 14 days prior to IV durvalumab administration. An additional six patients were entered into Arm II HD, receiving high dose IV VCN-01 (1.0E13 virus particles; HD) 14 days prior to IV durvalumab administration.
The trial enrolled 20 patients with advanced head and neck cancer who had failed prior treatments including checkpoint inhibitors. Patients were divided into three arms testing different doses and timing of VCN-01 combined with durvalumab, providing data on optimal dosing strategies for this difficult-to-treat patient population.
Added in current filing · verify on EDGAR →
Median progression-free survival (PFS) was 1.6 months in Arm I LD, 3.7 months in Arm II LD, and 2.1 months in Arm II HD. ·Median overall survival (OS) was 10.3 months in Arm I LD, 15.5 months in Arm II LD, and 17.3 months in Arm II HD.
The trial showed median overall survival ranging from 10.3 to 17.3 months across the three treatment arms, with the highest survival in the high-dose sequential arm. Progression-free survival ranged from 1.6 to 3.7 months. These results in heavily pre-treated patients provide key efficacy data for the VCN-01 program.
Added in current filing · verify on EDGAR →
Circulating levels of the stroma-degrading hyaluronidase enzyme PH20 (expressed during selective VCN-01 intratumoral replication) increased significantly after VCN-01 administration in all tested patients, peaking on day 3-8 for most patients and detectable until day 28 in 11 of 12 patients. ·Similarly, VCN-01 viral genome levels detected in patient blood exhibited an initial peak immediately following administration and a secondary peak on day 3-8, consistent with continued viral replication in tumors followed by a return of virus to circulation.
The trial demonstrated that VCN-01 successfully replicated in tumors, as evidenced by elevated PH20 enzyme levels and viral genome detection in patient blood. The secondary peak at days 3-8 suggests ongoing viral replication within tumors, providing proof-of-concept for the therapy's intended mechanism of action.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 11, 2026 · How we verify